Recommendations Developed for Antithrombotic Tx in VTE

Share this content:
Recommendations Developed for Antithrombotic Tx in VTE
Recommendations Developed for Antithrombotic Tx in VTE

TUESDAY, Jan. 12, 2016 (HealthDay News) -- New recommendations have been developed for antithrombotic therapy for venous thromboembolism (VTE). The Antithrombotic Therapy for VTE Disease: CHEST Guideline was published online Jan. 7 in CHEST.

Clive Kearon, M.D., Ph.D., from McMaster University in Hamilton, Canada, and colleagues updated recommendations for 12 topics and addressed three new topics related to antithrombotic therapy for VTE disease.

The guideline authors recommended dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonist (VKA) therapy, and VKA therapy over low molecular weight heparin (LMWH) as long-term anticoagulant therapy for VTE and no cancer. LMWH was suggested over VKA, dabigatran, rivaroxaban, apixaban, or edoxaban for VTE and cancer. Recommendations for who should stop anticoagulation at three months or receive extended therapy have not changed. The authors recommended against an inferior vena cava filter for VTE treated with anticoagulants. They also recommended not using compression stockings to routinely prevent post-thrombotic syndrome for deep vein thrombosis (DVT). Clinical surveillance was recommended over anticoagulation with a low risk of recurrent VTE, and anticoagulation over surveillance with a high risk, for patients with subsegmental pulmonary embolism and no proximal DVT.

"The guideline presents stronger recommendations and weaker suggestions for treatment based on the best available evidence, and identifies gaps in our knowledge and areas for future research," Kearon said in a news release from the American College of Chest Physicians.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WPSI Recommends Annual Urinary Incontinence Screening

WPSI Recommends Annual Urinary Incontinence Screening

Due to limited evidence, other experts urge caution in implementing guideline for women

Young, Growing Athletes at High Risk for ACL Injuries

Young, Growing Athletes at High Risk for ACL ...

Athletic teams should provide program that includes muscle strengthening, proper technique training

Side Effects of Biologics for Rheumatic Dz May Up Anxiety

Side Effects of Biologics for Rheumatic Dz May ...

Common patient concerns are risks of cancer and tuberculosis activation

is free, fast, and customized just for you!




Already a member?

Sign In Now »